Limits...
New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine.

Paggiaro P - Open Respir Med J (2009)

Bottom Line: Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed.This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low.Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP.

View Article: PubMed Central - PubMed

Affiliation: Cardio-Thoracic and Vascular Department, University of Pisa, Italy.

ABSTRACT
International asthma guidelines have recently focused on the concept of , which is the main outcome to reach and maintain in the long term management. Asthma control is associated with several positive consequences, both in terms of quality of life and pathophysiological findings. Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed. This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low. Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP. Recent studies have demonstrated the equivalence of this new combination with the other ICS/LABA combination, as regards all asthma outcomes. Then, this new BDP/formoterol combination may increase the possibility to manage adequately patients with moderate-to-severe asthma.

No MeSH data available.


Related in: MedlinePlus

Level of asthma control in patients treated with the new budesonide/formoterol extra-fine HFA formulation, the traditional combination by two distinct inhalers, or high dose beclomethasone alone [12].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2682924&req=5

Figure 3: Level of asthma control in patients treated with the new budesonide/formoterol extra-fine HFA formulation, the traditional combination by two distinct inhalers, or high dose beclomethasone alone [12].

Mentions: Some studies have been performed in order to demonstrate the efficacy of this new BDP/Formoterol combination. A first study was done in order to compare the new combination with the combination with BDP at higher doses in the traditional CFC formulation plus inhaled formoterol, administered with two different inhalers; a third group of patients was treated with BDP alone in the traditional CFC formulation [12]. The study shows that the new BDP/Formoterol combination was equivalent to the traditional extemporary combination with higher doses of BDP in terms of pulmonary function and rate of severe exacerbations, but it was better than comparators as regards the percentage of days without asthma symptoms or of days with asthma control (Fig. 3). Notably, morning serum cortisol levels increased significantly versus baseline with BDP/formoterol, but remained substantially unchanged with the other regimens, suggesting that the control of asthma could be maintained at least as well as with traditional higher doses of BDP with the potential for lower side effects.


New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine.

Paggiaro P - Open Respir Med J (2009)

Level of asthma control in patients treated with the new budesonide/formoterol extra-fine HFA formulation, the traditional combination by two distinct inhalers, or high dose beclomethasone alone [12].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2682924&req=5

Figure 3: Level of asthma control in patients treated with the new budesonide/formoterol extra-fine HFA formulation, the traditional combination by two distinct inhalers, or high dose beclomethasone alone [12].
Mentions: Some studies have been performed in order to demonstrate the efficacy of this new BDP/Formoterol combination. A first study was done in order to compare the new combination with the combination with BDP at higher doses in the traditional CFC formulation plus inhaled formoterol, administered with two different inhalers; a third group of patients was treated with BDP alone in the traditional CFC formulation [12]. The study shows that the new BDP/Formoterol combination was equivalent to the traditional extemporary combination with higher doses of BDP in terms of pulmonary function and rate of severe exacerbations, but it was better than comparators as regards the percentage of days without asthma symptoms or of days with asthma control (Fig. 3). Notably, morning serum cortisol levels increased significantly versus baseline with BDP/formoterol, but remained substantially unchanged with the other regimens, suggesting that the control of asthma could be maintained at least as well as with traditional higher doses of BDP with the potential for lower side effects.

Bottom Line: Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed.This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low.Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP.

View Article: PubMed Central - PubMed

Affiliation: Cardio-Thoracic and Vascular Department, University of Pisa, Italy.

ABSTRACT
International asthma guidelines have recently focused on the concept of , which is the main outcome to reach and maintain in the long term management. Asthma control is associated with several positive consequences, both in terms of quality of life and pathophysiological findings. Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed. This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low. Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP. Recent studies have demonstrated the equivalence of this new combination with the other ICS/LABA combination, as regards all asthma outcomes. Then, this new BDP/formoterol combination may increase the possibility to manage adequately patients with moderate-to-severe asthma.

No MeSH data available.


Related in: MedlinePlus